Literature DB >> 16698238

Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions.

David M Johnson1, Thomas R Fritsche, Helio S Sader, Ronald N Jones.   

Abstract

Dalbavancin is a potent, once-weekly administered lipoglycopeptide that is active against a broad spectrum of Gram-positive species. Synergy studies were performed with dalbavancin and each of nine antimicrobial agents (90 tests in total) representing nine antimicrobial classes using the broth microdilution checkerboard method to establish in vitro interactive categories. Antagonism was not observed between dalbavancin and any of the antimicrobials tested. However, dalbavancin was synergistic or partially synergistic with oxacillin for staphylococci, including methicillin-resistant strains, vancomycin-intermediate Staphylococcus aureus and enterococci, a significant finding that warrants further investigation to establish its potential clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698238     DOI: 10.1016/j.ijantimicag.2005.12.015

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  11 in total

1.  Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.

Authors:  Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

Review 2.  Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 3.  Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 4.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 5.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

Review 6.  Dalbavancin for the treatment of acute bacterial skin and skin structure infections.

Authors:  Sheena Ramdeen; Helen W Boucher
Journal:  Expert Opin Pharmacother       Date:  2015-08-04       Impact factor: 3.889

Review 7.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 8.  Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Authors:  Kimberly D Leuthner; Kristin A Buechler; David Kogan; Agafe Saguros; H Stephen Lee
Journal:  Ther Clin Risk Manag       Date:  2016-06-07       Impact factor: 2.423

9.  Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review.

Authors:  Jason W Bennett; James S Lewis; Michael W Ellis
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

10.  Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.

Authors:  Jordan R Smith; Karrine D Roberts; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2015-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.